ArticleEuropean journal of epidemiology2025
Completeness and generalizability of the Swedish MS register.
Article in European journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Polypharmacy, Potential Drug-Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study.Neurology and therapy · 2026Article
- Genetic modification of obesity-associated disability progression in multiple sclerosis.Journal of neurology · 2026Article
- Interaction between smoking andMultiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Migration status, country of origin and long-term outcomes in multiple sclerosis: a Swedish nationwide study.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B-Cell Depletion.European journal of neurology · 2026Article
- Temporal Trends in the Incidence and Prevalence of Multiple Sclerosis in Sweden, 2001-2021.Neuroepidemiology · 2026Article
- Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis.Journal of neurology · 2026Article
- Disability progression in multiple sclerosis: a latent class analysis of predictors.Journal of neurology · 2026Article
- Determinants and prognostic value of onset symptoms in multiple sclerosis.Journal of neurology · 2025Article
- Identifying strategies to characterize the diversity of the MS population in Canada: a nominal group study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Swedish Multiple Sclerosis (MS) Register is a nationwide clinical tool and research database. Its generalizability to the broader MS population has not been previously assessed. We aimed to quantify the register's completeness and potential disparities between those who were included and those who were not. Using linked national registers, we identified persons with MS through December 2020 as those with ≥ 3 MS diagnoses in the National Patient Register. We assessed the MS register's completeness and compared characteristics between included and non-included persons, using overlap weighting to account for age differences. Among 21,320 prevalent (2020) and 7,355 incident (2011-2020) MS cases, the completeness of the MS register was 85% and 87%, respectively, but varied by county (67-94% in 2020). Prevalent cases not included in the register were older (mean 62.4 vs. 52.3 years) and more likely to have no salaried income (55.3% vs. 30.5%); had fewer years of education (20.8% vs. 12.0% with ≤ 9 years); more often been hospitalized (41.5% vs. 32.2%); and collected more unique prescribed drugs (median 7 vs. 5 drugs per year). Incident cases were also older at first MS diagnosis (mean 50.3 vs. 39.2 years). All differences were attenuated by adjusting for age, although disparities remained. The Swedish MS Register demonstrates high completeness, but may not fully represent older persons with MS, those diagnosed later in life, and those of lower socioeconomic status. These limitations should be considered when interpreting findings based on the register's data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.